• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

澳大利亚脑膜炎球菌监测项目2007年年度报告——修订版

Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended.

作者信息

Tapsall John

机构信息

Department of Microbiology, SEALS, The Prince of Wales Hospital, Randwick, NSW.

出版信息

Commun Dis Intell Q Rep. 2009 Mar;33(1):1-9.

PMID:19618762
Abstract

In 2007 there were 281 laboratory-confirmed cases of invasive meningococcal disease analysed by the National Neisseria Network, a nationwide network of reference laboratories. The phenotypes (serogroup, serotype and serosubtype) and antibiotic susceptibility of 154 isolates of Neisseria meningitidis from invasive cases of meningococcal disease were determined and an additional 127 cases were confirmed by non-culture based methods. Nationally, 223 (85%) confirmed cases where a serogroup was determined were infected with serogroup B and 17 (6.5%) with serogroup C meningococci. The total number of confirmed cases was 10 more than the 271 cases identified in 2006. Queensland and New South Wales recorded slight increases in case numbers and Victoria recorded a decline. Typical primary and secondary disease peaks were observed in those aged 4 years or less and in adolescents and young adults respectively. Serogroup B cases predominated in all age groups and jurisdictions. The common phenotypes circulating in Australia were B:15:P1.7, B:4:P1.4 and C:2a:P1.5. No evidence of meningococcal capsular 'switching' was detected. About three-quarters of all isolates showed decreased susceptibility to the penicillin group of antibiotics (MIC 0.06-0.5 mg/L). All isolates remained susceptible to rifampicin. A single serogroup B isolate had decreased susceptibility to ciprofloxacin (MIC 0.06 mg/L). This was the first local isolate of this type since the original report of this phenomenon in Australia in 2000.

摘要

2007年,国家奈瑟菌网络(一个全国性的参考实验室网络)分析了281例实验室确诊的侵袭性脑膜炎球菌病病例。确定了154株来自侵袭性脑膜炎球菌病病例的脑膜炎奈瑟菌分离株的表型(血清群、血清型和血清亚型)及抗生素敏感性,另外127例通过非培养方法确诊。在全国范围内,223例(85%)确定血清群的确诊病例感染了B群脑膜炎球菌,17例(6.5%)感染了C群脑膜炎球菌。确诊病例总数比2006年确定的271例多10例。昆士兰州和新南威尔士州的病例数略有增加,维多利亚州的病例数有所下降。分别在4岁及以下儿童和青少年及青年中观察到典型的原发性和继发性疾病高峰。B群病例在所有年龄组和司法管辖区中占主导地位。在澳大利亚传播的常见表型为B:15:P1.7、B:4:P1.4和C:2a:P1.5。未检测到脑膜炎球菌荚膜“转换”的证据。所有分离株中约四分之三对青霉素类抗生素的敏感性降低(最低抑菌浓度为0.06 - 0.5毫克/升)。所有分离株对利福平仍敏感。一株B群分离株对环丙沙星的敏感性降低(最低抑菌浓度为0.06毫克/升)。这是自2000年澳大利亚首次报告该现象以来的首例此类本地分离株。

相似文献

1
Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended.澳大利亚脑膜炎球菌监测项目2007年年度报告——修订版
Commun Dis Intell Q Rep. 2009 Mar;33(1):1-9.
2
Annual report of the Australian Meningococcal Surveillance Programme, 2007.《2007年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2008 Sep;32(3):299-307.
3
Annual report of the Australian Meningococcal Surveillance Programme, 2008.《2008年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2009 Sep;33(3):259-67.
4
Annual report of the Australian Meningococcal Surveillance Programme, 2011.《2011年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2012 Sep 30;36(3):E251-62.
5
Annual report of the Australian Meningococcal Surveillance Programme, 2009.《2009年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2010 Sep;34(3):291-302.
6
Annual report of the Australian Meningococcal Surveillance Programme, 2006.
Commun Dis Intell Q Rep. 2007 Jun;31(2):185-94. doi: 10.33321/cdi.2007.31.14.
7
Annual report of the Australian Meningococcal Surveillance Programme, 2005.《2005年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2006;30(2):211-21. doi: 10.33321/cdi.2006.30.17.
8
Australian Meningococcal Surveillance Programme annual report, 2010.《2010年澳大利亚脑膜炎球菌监测计划年度报告》
Commun Dis Intell Q Rep. 2011 Sep;35(3):217-28.
9
Annual report of the Australian Meningococcal Surveillance Programme, 2000.
Commun Dis Intell Q Rep. 2001 Aug;25(3):113-21. doi: 10.33321/cdi.2001.25.23.
10
Annual report of the Australian Meningococcal Surveillance Programme, 2003.《2003年澳大利亚脑膜炎球菌监测项目年度报告》
Commun Dis Intell Q Rep. 2004;28(2):194-206. doi: 10.33321/cdi.2004.28.17.

引用本文的文献

1
Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.疫苗预防非洲的脑膜炎球菌病:重大进展,尚存挑战。
Hum Vaccin Immunother. 2018 May 4;14(5):1107-1115. doi: 10.1080/21645515.2017.1412020. Epub 2018 Jan 16.
2
Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.一种与常规疫苗同时接种的CRM结合型脑膜炎球菌ACWY疫苗从2月龄开始接种时的免疫原性和安全性。
Hum Vaccin Immunother. 2014;10(2):280-9. doi: 10.4161/hv.27051. Epub 2013 Nov 12.